- IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
-
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
- -
-
Paragraph 00166
(2018/04/12)
-
- TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
-
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
- -
-
Paragraph 0355; 0356
(2016/07/27)
-
- HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES
-
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
- -
-
Page/Page column 84
(2015/11/09)
-
- PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES
-
The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
- -
-
Paragraph 0415; 0416; 0417
(2015/06/24)
-
- Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1, 5-a]-1,3,5-triazines: Potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists
-
This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF1 IC50 = 6.1 ± 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.
- Gilligan, Paul J.,Clarke, Todd,He, Liqi,Lelas, Snjezana,Li, Yu-Wen,Heman, Karen,Fitzgerald, Lawrence,Miller, Keith,Zhang, Ge,Marshall, Anne,Krause, Carol,McElroy, John F.,Ward, Kathyrn,Zeller, Kim,Wong, Harvey,Bai, Steven,Saye, Joanne,Grossman, Scott,Zaczek, Robert,Arneric, Stephen P.,Hartig, Paul,Robertson, David,Trainor, George
-
experimental part
p. 3084 - 3092
(2010/02/28)
-
- (Hetero)-aryl ketones derivatives with antibacterial properties
-
Conformationally restricted aryl and heteroaryl ketones derived from monic acid have useful antibacterial properties.
- -
-
-
- Preparation of E-(2-substituted-1-methylethylidene)indanones derived from monic acid
-
Alkylation of the lithium dienolate of the monic acid hydroxamate (3) with o-bromo(bromomethyl) benzene or heteroaromatic derivatives gave α-alkylated products (5). This alkylation procedure was surprisingly catalysed by 4- dimethylaminopyridine. Metal-halogen exchange with t-butyl lithium occurred with concomitant intramolecular cyclisation to give a mixture of the deconjugated ketones (6). Reconjugation with potassium t-butoxide stereoselectively produced the E-isomer (7). Deprotection gave the monic acid derived ketone (1).
- Pearson, Neil D.,Broom, Nigel J.P.,O'Hanlon, Peter J.
-
p. 3771 - 3774
(2007/10/02)
-